Alzheimer's & dementia (Amsterdam, Netherlands) · 2026
A prospective real-world study of the efficacy and safety of aducanumab in China: Focus on early-onset and autosomal dominant Alzheimer's disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xiao Jinwen, Li Binyin, Li Biao, Wang Jintao, Tang Ran, Gao Chao, Che Xiangqian, Xu Xiaomeng, Chen Shengdi, Ren Rujing, Wang Gang
Аннотация
INTRODUCTION: Aducanumab is the first anti-amyloid therapy used for Alzheimer's disease (AD) in China.
METHODS: This 12-month, single-center, real-world study enrolled 12 participants with early AD receiving aducanumab 10 mg/kg every 4 weeks (ChiCTR2200066153). The primary outcomes were changes in Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores at 12 months. Secondary outcomes included amyloid clearance, brain structure measures, and biomarker assessments.
RESULTS: No amyloid-related imaging abnormalities occurred. The mean CDR-SB score increased by 0.88 at 12 months, with cortical and hippocampal atrophy, enlarged choroid plexus, and ventricular volumes. Two autosomal dominant AD patients exhibited transient amyloid burden elevation at 6 months and subsequent reduction at 12 months, alongside increased serum glial fibrillary acidic protein (GFAP) levels. In the remaining 10 patients, the mean amyloid clearance reached -34.93 Centiloids, alongside decreased serum GFAP levels.
DISCUSSION: Aducanumab showed good tolerability and favorable biological outcomes, with different responses in autosomal dominant mutation carriers.
METHODS: This 12-month, single-center, real-world study enrolled 12 participants with early AD receiving aducanumab 10 mg/kg every 4 weeks (ChiCTR2200066153). The primary outcomes were changes in Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores at 12 months. Secondary outcomes included amyloid clearance, brain structure measures, and biomarker assessments.
RESULTS: No amyloid-related imaging abnormalities occurred. The mean CDR-SB score increased by 0.88 at 12 months, with cortical and hippocampal atrophy, enlarged choroid plexus, and ventricular volumes. Two autosomal dominant AD patients exhibited transient amyloid burden elevation at 6 months and subsequent reduction at 12 months, alongside increased serum glial fibrillary acidic protein (GFAP) levels. In the remaining 10 patients, the mean amyloid clearance reached -34.93 Centiloids, alongside decreased serum GFAP levels.
DISCUSSION: Aducanumab showed good tolerability and favorable biological outcomes, with different responses in autosomal dominant mutation carriers.